Exploring the Clinical Presentation, Course, and Burden of Disease in Generalized Pustular Psoriasis [Podcast] by Merola JF, Amin AZ

Get full text

Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting. by Gottlieb, AB, Coates, LC, van Mens, LJJ, Armstrong, AW, Merola, JF

Comparison of different remission and low disease definitions in patients with psoriatic arthritis and evaluation of their prognostic value by Coates, LC, Gottlieb, AB, Merola, JF, Boone, C, Szumski, A, Chhabra, A

Itch as the major mediator of the effect of tofacitinib on health-related quality of life in PSA: a mediation analysis by Taylor, P, Bushmakin, AG, Cappelleri, JC, Young, P, Germino, R, Merola, JF, Yosipovitch, G

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study by Petersen, MB, Hansen, RL, Egeberg, A, Jørgensen, TS, Merola, JF, Coates, LC, Kristensen, LE

Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis by Taylor, PC, Bushmakin, AG, Cappelleri, JC, Young, P, Germino, R, Merola, JF, Yosipovitch, G

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies by Taylor, P, Bushmakin, AG, Cappelleri, JC, Young, P, Germino, R, Merola, JF, Yosipovitch, G

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial by Kavanaugh, A, Coates, LC, Mease, PJ, Nowak, M, Hippeli, L, Lehman, T, Banerjee, S, Merola, JF

Guselkumab was more effective than secukinumab in patients with plaque psoriasis and the subset of patients with self-reported PsA in the randomised, double-blind, head-to-head com... by Merola, JF, Li, S, Hsu, M-C, Karyekar, C, Gorecki, PC, Flavin, S, Randazzo, B, Coates, LC

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and ski... by Taylor, PC, De Vlam, K, Bushmakin, AG, Fallon, L, Merola, JF, Cappelleri, JC, Hsu, MA, Mease, PJ

Screening/referral strategies for the early recognition of psoriatic arthritis (PsA) among patients with psoriasis: results of a GRAPPA survey by Song, K, Eder, L, FitzGerald, O, Goel, N, Helliwell, PS, Katz, A, Merola, JF, Rosen, CF, Coates, L, Poddubnyy, D

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis by Coates, LC, Smolen, JS, Mease, PJ, Husni, ME, Merola, JF, Lespessailles, E, Kishimoto, M, Macpherson, L, Bradley, AJ, Bolce, R, Helliwell, PS

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis by de Vlam, K, Mease, PJ, Bushmakin, AG, Fleischmann, R, Ogdie, A, Azevedo, VF, Merola, JF, Woolcott, J, Cappelleri, JC, Fallon, L, Taylor, PC

Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study by Aletaha D, Husni ME, Merola JF, Ranza R, Bertheussen H, Lippe R, Young PM, Cappelleri JC, Brown TM, Ervin C, Hsu MA, Fallon L

Get full text

In psoriatic arthritis fatigue is driven by inflammation, disease duration, and chronic pain: An observational DANBIO registry study by Skougaard, M, Jørgensen, TS, Rifbjerg-Madsen, S, Coates, LC, Egeberg, A, Amris, K, Dreyer, L, Højgaard, P, Guldberg-Møller, J, Merola, JF, Frederiksen, P, Gudbergsen, H, Kristensen, LE

Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial by Gossec, L, Coates, LC, Gladman, DD, Aelion, J, Vasandani, J, Pinter, A, Merola, JF, Kavanaugh, A, Reddy, J, Wang, R, Brunori, M, Klyachkin, Y, Deignan, C, Mease, P

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies by Mease, PJ, Merola, JF, Tanaka, Y, Gossec, L, McInnes, IB, Ritchlin, CT, Landewé, RBM, Asahina, A, Ink, B, Heinrichs, A, Bajracharya, R, Shende, V, Coarse, J, Coates, LC

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis by Coates, L, Merola, JF, Mease, PJ, Ogdie, A, Gladman, DD, Strand, V, van Mens, L J.J., Liu, L, Yen, PK, Collier, DH, Kricorian, G, Chung, JB, Helliwell, PS

Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study by Skougaard, M, Jørgensen, TS, Jensen, MJ, Ballegaard, C, Guldberg-Møller, J, Egeberg, A, Christensen, R, Benzin, P, Stisen, ZR, Merola, JF, Coates, LC, Strand, V, Mease, P, Kristensen, LE

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active... by Ritchlin, CT, Coates, LC, McInnes, IB, Mease, PJ, Merola, JF, Tanaka, Y, Asahina, A, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Landewé, R